These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32593470)

  • 1. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
    Scherber RM; Mesa RA
    Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
    Hunter AM; Bose P
    Expert Opin Pharmacother; 2024 Jul; 25(10):1391-1404. PubMed ID: 39067001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
    Saleh K; Ribrag V
    Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
    Bose P; Mesa RA
    Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
    Gill H; Leung GMK; Kwong YL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.
    Loscocco GG; Vannucchi AM
    Int J Hematol; 2022 May; 115(5):626-644. PubMed ID: 35352288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
    Saha C; Harrison C
    Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.
    Scherber RM; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):118-126. PubMed ID: 30504300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Perspectives on a new therapeutic approach for myeloproliferative neoplasms].
    Kirito K
    Rinsho Ketsueki; 2021; 62(6):582-591. PubMed ID: 34219084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
    Lee SS; Verstovsek S; Pemmaraju N
    J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.